English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Context   l -Thyroxine ( l -T4) therapy of central hypothyroidism (CH) is guided by measurements of serum free thyroxine (FT4), which should be above the midnormal range value (MNRV). In some countries, novel formulations of oral  l -T4 (liquid or softgel) are available further to the classic tablets. The intestinal absorption of either novel formulation is greater than tablets in patients with primary hypothyroidism.    Objective  To evaluate whether new oral formulations of  l -T4 could be considered optimal in patients with CH who do not reach the FT4 target using tablet  l -T4.    Design  Our observation of six patients with isolated CH and serum FT4 below MNRV under stable adequate doses of tablet  l -T4 (median 1.51 μg/kg bw/day), prompted us to switch them to liquid ( n  = 4) or softgel ( n  = 3)  l -T4 at the same dose, and verify whether FT4 increased above MNRV. A seventh patient with FT4 above MNRV was enrolled because she wanted a “ more modern formulation .” Postswitch FT4 was measured at least twice with the same kit as preswitch FT4.    Results  In the first six patients, postswitch FT4 averaged 13.0 ± 1.6 pg/ml compared to 10.4 ± 1.8 preswitch FT4 ( P  = 0.00026), with 11/13 (85%) measurements above MNRV compared to 0/20. In the liquid or softgel  l -T4 group, postswitch FT4 averaged 13.1 ± 1.6 vs. 10.6 ± 0.9 pg/ml preswitch ( P  = 0.0004) or 12.9 ± 2.1 vs. 10.3 ± 2.4 ( P  = 0.048), respectively. In the seventh patient (switched to liquid  l -T4), averages were 18.3 vs. 15.2 pg/ml, and proportions 4/4 vs. 2/2.    Conclusion  In CH patients, oral liquid or softgel  l -T4 administered at the same doses as tablet  l -T4 ensures target serum FT4 levels above MNRV that tablet  l -T4 may miss. In turn, this performance suggests the more favorable pharmacokinetics profile of either novel formulation compared with the tablet formulation.

l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism